

# Vitamin D deficiency: A review of the relationship between vitamin Deficiencies somedisease as Obesity, Diabetes and Cardiovascular in Al-Muthanna Province - Iraq

Hanaa Ali Aziz<sup>1</sup>, Dhay Ali Azeez<sup>2</sup>  
*1,2College of Science, Al-Muthanna University, Iraq*

## *Abstract*

*Vitamin D deficiency is pandemic, and has been implicated in a wide variety of disease such obesity, diabetes and cardiovascular. Recent studies have found a relationship between vitamin D deficiency and an increase in the weight of people, it showed the presence of an enzyme responsible for the formation of vitamin D and the efficacy of metabolism , The lower action of this enzyme leads to a lack of vitamins and hence the low level of metabolic activity in people. Vitamin D deficiency predisposes individuals to type 1 and type 2 diabetes, and receptors for its activated form 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> have been identified in both beta cells and immune cells. The researchers shown role in the development of type 2 diabetes through impair insulin synthesis and secretion in humans and animal models. Also , epidemiological studies suggest a link between vitamin D deficiency in early life and the later onset of type 1 diabetes. Also, several studies have reported that vitamin D deficiency is associated with increased risk of cardiovascular disease, including hypertension, heart failure and ischemic heart disease.*

*Keywords: Vitamin D; Obesity , Diabetes , Cardiovascular.*

---

## **1. Introduction**

The term vitamin D refers to the product that is in food (vitamins D<sub>2</sub> and D<sub>3</sub>) and is synthesized in the skin under the influence of UVB radiation (vitamin D<sub>3</sub>), whereas the metabolically active molecule is referred to as 1,25 (OH)<sub>2</sub>D<sub>3</sub>[13]. Vitamin D is a fat-soluble vitamin known as calciferol. The two major forms of this vitamin are vitamin D<sub>2</sub> (ergocalciferol) and vitamin D<sub>3</sub> (cholecalciferol). Vitamin D is the only vitamin that can be manufactured by the body and therefore is sometimes referred to as a hormone as well as a vitamin[9]. The sun (UV-B irradiation) triggers a reaction in the skin that converts pro vitamin D to active vitamin D<sub>3</sub> which is then transported to the liver and kidneys for further processing , but the excess vitamin D is stored in fat tissue[28]. Our diet is another source of vitamin D as it can be absorbed through our intestine, Vitamin D is found naturally in a few products such as dairy products , Cheese , Butter , Cream ,Fortified milk , Fish ( Salmon, mackerel, sardines, herring, tuna ) , Fish oils , Egg yolks , Oysters ,Fortified cereal, Fortified juices[9].some researchers have recommended to be taken Vitamin D supplements that contain either cholecalciferol (vitamin D<sub>3</sub>) or ergocalciferol (vitamin D<sub>2</sub>) with meals because the oily or fatty foods will cause the release of bile into the stomach which will increased absorption of the vitamin. Some studies indicate that vitamin D<sub>3</sub> may work more efficiently and be superior to vitamin D<sub>2</sub> [28].

### **Measuring Vitamin D levels**

The level of vitamin D in our blood is measured by a 25(OH) D level and it is believed that a sufficient level of this vitamin in the blood ranges between 30-60 ng/ml [27].

Vitamin D insufficiency: 25(OH)D levels of 20 to 30 ng/ml  
Vitamin D deficiency: 25(OH)D levels of below 20 ng/ml

Vitamin D toxicity: 25(OH)D levels of over 150 ng/ml

### **Vitamin D deficiency**

There are certain groups of people that have an increased risk for vitamin D deficiency. These groups include [40]:-

- 1- Solely breast-fed infants older than 2 months of age
- 2- Individuals older than 50 years of age
- 3- Persons living in residential care facilities
- 4- Persons with problems absorbing fat, which includes those with:
  - Cystic fibrosis
  - Crohn's disease
  - Celiac disease
- Some liver diseases
- 5- Persons with kidney disease, especially those requiring dialysis
- 6- Persons that have had gastric bypass surgery
- 7- Darker-skinned individuals
- 8- Persons using sunscreen (SPF8 or higher)
- 9- Obese individuals
- 10- Persons treated with certain drugs that may interfere with absorption or activity of the vitamin:
  - Anti seizure drugs such as phenytoin, phenobarbital, and carbamazepine.
  - Drugs used to treat tuberculosis such as isoniazid and rifampin.
  - Other drugs including corticosteroids, theophylline (an asthma drug).

Chronic severe vitamin D deficiency in infants and children causes abnormal bones and it leads to rickets. While in adults, that causes muscle weakness, bone pain and osteoporosis and due to much higher risk for fractures especially in the elderly [5].

### **Vitamin D and Obesity**

Obesity is pandemic, defined by the World Health Organization as a body mass index (BMI) of 30 kg/m<sup>2</sup> or more, affecting on the substantial numbers of people in most developed nations [17]. Overweight is included BMI (25–29.9), approximately 14 million Australians and 70% of Americans aged over 60, are obese or overweight [2]. Older people that suffering excess body fat accumulation face increased risk for coronary heart disease, hypertension, metabolic syndrome, osteoarthritis, diabetes mellitus, and other co-morbidities [8]. It is necessary to identify obesity risk factors, especially those that can be easily treated. In the published literature they found association between increasing BMI and lower serum 25-hydroxyvitamin D (25D) concentrations [8]. Early, the studies reported an association between obesity and low serum 25D concentrations, as well as high concentrations of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25D) [3]. Also been reported that body fat content is inversely related to serum 25D concentration, and that this association is stronger than those between 25D and BMI and body weight [2]. The association between reduced 25D concentrations and obesity is well-established, therefore the mechanisms for the lower 25D concentrations are not fully described, and there is uncertainty as to what the health consequences of these lower concentrations might be [10].

### **Reduced Activation and/or Increased Catabolism**

Vitamin D acts to limit production of its precursor, early studies suggested that 1,25D concentrations were elevated in obese individuals, it was thought that this may lower 25D levels [14]. Given that further, larger studies have suggested that 1,25D concentrations tend to be lower in obese individuals, this feedback mechanism is unlikely to be relevant [39]. Adipose tissue (AT) in obese women expresses the enzymes for both the formation of 25D and its active

metabolite, 1,25D and for degradation of vitamin D [11]. Subcutaneous Adipose tissue has also been found to have lower expression of one of the enzymes responsible for 25-hydroxylation of vitamin D (CYP2J2), as well as a tendency toward a decreased expression of the 1- $\alpha$  hydroxylase[30]. These data suggest that both 25-hydroxylation and 1- $\alpha$  hydroxylation are impaired in obesity. In vitro studies have demonstrated that 1,25D inhibits adiposeness and induces adipocyte apoptosis [14]. Under normal physiological conditions the serum 1,25D concentration is tightly regulated, but there can be significant differences between 1,25D concentrations within different tissues owing to in situ production[15]. There is also evidence that weight loss leads to increased 25D concentrations, which may in turn provide additional protection against chronic disease[15].

Table (1.1): WHO Classification of under and overweight in adults according to BMI.

Classification	BMI (kg/M2)	Risk of Comorbidities
Underweight	<18.5	Low
Healthy Weight	18.5-24.9	Average
Overweight	25.0-29.9	Increased
Obese Class I	30.0-34.9	Moderate
Obese Class II	35.0-39.9	Severe
(Obese Class III (Morbid))	>40.0	Very Severe

Obesity has been suggested to be a risk factor for vitamin D deficiency, The inverse association between higher body fat and lower vitamin D levels has been attributed to sequestration of the fat-soluble vitamin within the plentiful adipose tissue[9]. National population-based data are lacking of the prevalence risk factors for vitamin D deficiency among over weight and obese children. Identifying vitamin D deficiency in these children may be particularly important for their skeletal and cardiovascular health[15]. The research suggests that vitamin D deficiency increases the risk of these conditions Fractures, Blount disease, and slipped capital femoral epiphysis are more common in obese children[15]. Cardiovascular disease risk factors and impaired glucose homeostasis also are associated with vitamin D deficiency , these are more common in overweight and obese children[9]. The prevalence of vitamin D deficiency among children classified into clinically useful BMI percentile categories (overweight, obese, and severely obese) may inform the need for screening and treatment of vitamin D deficiency by primary care physicians[27].

### Vitamin D and diabetes

The discovery of receptors for 1,25-dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) that activated form of vitamin D, in tissues with no direct role in calcium and bone metabolism (e.g. pancreatic beta cells and cells of the immune system), It showed the physiological role of this molecule[23]. An increased of type 2 diabetes has been described in vitamin D-deficient individuals [16]. Also insulin synthesis and secretion have been shown to be impaired in beta cells from vitamin D-deficient and glucose tolerance is restored when vitamin D levels return to normal[21]. The determined of receptors for 1,25(OH)<sub>2</sub>D<sub>3</sub> in cells of the immune system led to experiments in animal models of type 1 diabetes in which the giving of high doses of 1,25(OH)<sub>2</sub>D<sub>3</sub> was shown to prevent type 1 diabetes mainly through immune regulation[21]. It has been demonstrated that 1,25(OH)<sub>2</sub>D<sub>3</sub> is one of the most powerful blockers of dendritic cell differentiation and that it directly blocks IL-12 secretion, Lymphocyte proliferation is inhibited and regulator cell development is enhanced [23]. The role of vitamin D in type 1 and type 2 diabetes is clear, and it is possible applications of the molecule or its synthetic analogues in clinical disease[26].

### Vitamin D and type 2 diabetes

Vitamin D deficiency was linked to type 2 diabetes in humans many years ago [4]. These observations were confirmed in animal models, which determined that pancreatic insulin secretion is inhibited by vitamin D deficiency [23]. Several reports have ascribed an active role to vitamin D in the functional regulation of the endocrine pancreas, particularly the beta cells[4]. Not only are receptors for 1,25(OH)<sub>2</sub>D<sub>3</sub> found in beta cells but the effector part of the vitamin D

pathway is also present in the form of vitamin D-dependent calcium-binding protein, also known as calbindin-D28k [33]. The expression of calbindin-D28K has been shown to protect beta cells from cytokine-mediated cell death [29]. Several studies have demonstrated a link between VDR gene polymorphisms and type 2 diabetes, although the findings differ from one population to another[26]. A study in Bangladeshi Asians demonstrated that the ApaI RFLP influences insulin secretion in response to glucose [24]. While associations between the VDR ApaI RFLP and higher fasting plasma glucose levels and glucose intolerance were observed in a community-based study of older adults without known diabetes [24]. More recently, genotyping for TaqI, ApaI, BsmI and FokI RFLPs revealed that the BsmI RFLP is associated with high fasting glucose levels in young males with low physical activity[25].

### **Vitamin D and type 1 diabetes**

Several epidemiological studies have described correlation between geographical latitude and the incidence of type 1 diabetes, and an inverse correlation between monthly hours of sunshine and the incidence of diabetes[20]. A seasonal pattern of disease onset has also been described for type 1 diabetes, once again suggesting an inverse correlation between sunlight and the disease[16]. Vitamin D is an obvious candidate as a mediator of this sunshine effect[41]. Dietary vitamin D supplementation is often recommended in pregnant women and in children to prevent vitamin D deficiency[32]. Cod liver oil taken during the first year of life, its reduced the risk of childhood-onset type 1 diabetes [32]. Also, a multicenter case-control study also showed an association between vitamin D supplementation in infancy and a decreased risk of type 1 diabetes [35]. A further study found that an intake of 2,000 IU of vitamin D during the first year of life decrease the risk of developing type 1 diabetes, and showed that the incidence of childhood diabetes was three times higher in subjects with suspected rickets [12]. More recently, the Diabetes Autoimmunity Study in the Young (DAISY) reported that the presence of islet auto-antibodies in offspring was inversely correlated with maternal dietary vitamin D intake during pregnancy [1]. It remains to be determined whether these observations are the result of supplementation of vitamin D to supra-physiological levels, or are simply the result of the prevention of vitamin D deficiency[7]. Observations in animal models suggest the latter, since regular supplements of vitamin D in neonatal and early life offered no protection against type 1 diabetes in nonobese diabetic (NOD) mice or in BioBreeding (BB) rats, whereas the prevalence of diabetes is doubled in NOD mice rendered vitamin D-deficient in early life[19]. The results of genetic studies investigating a possible relationship between VDR polymorphisms and type 1 diabetes are highly confusing: a clear correlation exist in some populations whereas no correlation can be found in others [22].

**Vitamin D and Cardiovascular Disease** Vitamin D as a direct factor on cardiac tissues and the vasculature during a few *in vitro* and *in vivo* studies, especially in response to injury[34]. They demonstrated that matrix metalloproteinase (MMP) that contribute to aberrant cardiomyocyte remodeling in response to injury and atherosclerosis[38]. Vitamin D receptor have impaired cardiac relaxation and contractility and develop left ventricular hypertrophy and Clinical studies have evaluated the role of vitamin D directly on the vasculature[17]. A cross-sectional study of subjects with ESRD demonstrated a significant positive correlation between vitamin D and arterial compliance that's measured by brachial artery flow mediated dilation and a negative correlation between aortic pulse wave velocity, both findings indicating decreased vascular compliance[18]. Vitamin D (1,25-hydroxyvitamin D) inhibited pro-fibrotic markers *in vitro* using mesenchyme multipotent cells, suggesting that vitamin D may also have a direct effect on the vasculature in response to injury[6]. Also, diabetic patients that ingested a large dose of vitamin D (100,000 IU) had significant improvement in endothelial function measured by flow mediated dilation and decrease in blood pressure[36]. Finally, a recent randomized controlled trial of vitamin D supplementation on people with heart failure and demonstrated significant reductions in inflammatory cytokines involved in the pathophysiology of heart failure[31].

## Conclusion

Vitamin D insufficiency is very common in the world. Several recent studies have demonstrated association between vitamin D insufficiency and risk of injury of obesity, diabetes and cardiovascular disease. It showed association between reduced 25D concentrations and obesity they can be determined by a volumetric dilatational model. Thus, the obese individuals requires higher doses from vitamin D than the general population. Also, showed evidence exists that vitamin D deficiency arecauses damages to beta cells function and leads to glucose intolerance in animal and humans thus the individuals are suffering predisposes to type 2 diabetes. They found Vitamin D deficiency in early life predisposes humans then development of autoimmune diabetes. A major conclusion that can be drawn from the studies includes that vitamin D deficiency is not only effect on calcium and bone, but also for glucose metabolism. Finally, Several studies have suggested that vitamin D deficiency predisposes individuals to increased risk of incident hypertension, ischemic heart disease, sudden cardiac death or heart failure.

## References

- 1- Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. *J Endocrinol* Feb;(2009) 200(2): 207–21. [PubMed: 19036760]
- 2- Arunabh, S.; Pollack, S.; Yeh, J.; Aloia, J.F. Body fat content and 25-hydroxyvitamin D levels in healthy women. *J. Clin. Endocrinol. Metab.* (2003), 88, 157–161.
- 3-Bouillon R, Verstuyf A, Verlinden L, Eelen G, Mathieu C (2003) Prospects for vitamin D receptor modulators as candidate drugs for cancer and (auto)immune diseases. *Recent Results Cancer Res* 164:353–356.
- 4-Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 79:820–825.
- 5-Dawson-Hughes, B(2008). Treatment of Vitamin D Deficient States. In: *Up To Date*, Basow, DS (Ed). Up To Date, Waltham, MA.
- 6-Fronczak CM, Baron AE, Chase HP et al (2003) In utero dietary exposures and risk of islet autoimmunity in children. *Diabetes Care* 26:3237–3242.
- 7-Giulietti A, Gysemans C, Stoffels K et al (2004) Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. *Diabetologia* 47:451–462.
- 8-Goodpaster, B.; Krishnaswami, S.; Harris, T.; Katsiaras, A.; Kritchevsky, S.; Simonsick, E.; Nevitt, M.; Holvoet, P.; Newman, A. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. *Arch. Int. Med.* (2005), 165, 777–783.
- 9-Holick, M. (2006). High Prevalence of Vitamin D Inadequacy and Implications for Health. *Mayo Clin Proc*; 81 (3):353-373.
- 10-Holick MF (2003) Vitamin D: a millenium perspective. *J Cell Biochem* 88:296–307.
- 11-hydroxyvitamin D in overweight or obese women. *Obesity* (2012), 20, 2296–2301.
- 12-Hyponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. *Lancet* 358:1500–1503.
- 13-Isaia G, Giorgino R, Adami S (2001) High prevalence of hypovitaminosis D in female type 2 diabetic population. *Diabetes Care* 24:1496.
- 14-Kong, J.; Li, Y.C. Molecular mechanism of 1,25-dihydroxyvitamin D<sub>3</sub> inhibition of adipogenesis in 3T3-L1 cells. *Am. J. Physiol. Endocrinol. Metab.* (2006), 290, E916–E924.
- 15-Lagunova, Z.; Porojnicu, A.; Lindberg, F.; Hexeberg, S.; Moan, J. The dependency of vitamin D status on body mass index, gender, age and season. *Anticancer Res.* (2009), 29, 3713–3720.
- 16-Lementowski, P.; Zelicof, S. Obesity and osteoarthritis. *Am. J. Orthop.* (2008), 37, 148–151.
- 17-Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D<sub>3</sub> is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* Jul;(2002) 110(2):229–38. [PubMed: 12122115].
- 18-London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Métivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. *J Am Soc Nephrol* Feb;(2007) 18(2):613–20. [PubMed: 17202417].
- 19-Mathieu C, Van Etten E, Decallonne B et al (2004) Vitamin D and 1,25-dihydroxyvitamin D<sub>3</sub> as modulators in the immune system. *J Steroid Biochem Mol Biol* 89–90:449–452.
- 20-Mathieu C, Van Etten E, Gysemans C, Decallonne B, Bouillon R (2002) Seasonality of birth in patients with type 1 diabetes. *Lancet* 359:1248.
- 21-Motohashi Y, Yamada S, Yanagawa T et al (2003) Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. *J Clin Endocrinol Metab* 88:3137–3140.
- 22-Nejentsev S, Cooper JD, Godfrey L et al (2004) Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. *Diabetes* 53:2709–2712.
- 23-Noncommunicable Diseases Country Profiles; World Health Organisation: Geneva, Switzerland, (2011); p. 209.

- 24-Oh JY, Barrett-Connor E (2002) Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. *Metabolism* 51:356–359.
- 25-Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R (2003) The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. *Diabet Med* 20:451–454.
- 26-Parikh, S.J.; Edelman, M.; Uwaifo, G.I.; Freedman, R.J.; Semega-Janneh, M.; Reynolds, J.; Yanovski, J.A. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. *J. Clin. Endocrinol. Metab.* (2004), 89, 1196–1199.
- 27-Pazirandeh, S; Burns, D, Waltham, MA, (2008). Overview of Vitamin D. In: Up To Date, Basow, DS (Ed). Up To Date.
- 28-Pilz, S; Tomashitz, A; Eberhard, R; Pieber, T(2009). Vitamin D Status and Arterial Hypertension: A Systematic Review, Oct.
- 29-Pi-Sunyer, F.X. The obesity epidemic: Pathophysiology and consequences of obesity. *Obes. Res.* (2002), 10, 97S–104S.
- 30-Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S (2001) Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. *Endocrinology* 142:3649–3655.
- 31-Rock, C.L.; Emond, J.A.; Flatt, S.W.; Heath, D.D.; Karanja, N.; Pakiz, B.; Sherwood, N.E.; Thomson, C.A. Weight loss is associated with increased serum.
- 32-Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr* Apr;(2006) 83(4):754–9. [PubMed: 16600924].
- 33-Sergeev, I. 1,25-dihydroxyvitamin D<sub>3</sub> induces Ca<sup>2+</sup>-mediated apoptosis in adipocytes via activation of calpain and caspase-12. *Biochem. Biophys. Res. Commun.* (2009), 384, 18–21.
- 34- Stene LC, Joner G (2003) Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. *Am J Clin Nutr* 78:1128–1
- 35- Stranges, S.; Trevisan, M.; Dorn, J.; Dmochowski, J.; Donahue, R. Body fat distribution, liver enzymes, and risk of hypertension: Evidence from the western New York study. *Hypertension* (2005), 46, 1186–1193.
- 36- Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. *J Steroid Biochem Mol Biol Mar*;(2007) 103(35):521–4. [PubMed: 17275289].
- 37-Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. *Diabet Med Mar*;(2008)25(3):320–5. [PubMed: 18279409].
- 38-van Halteren AG, Van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C (2002) Redirection of human autoreactive T cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D<sub>3</sub>. *Diabetes* 51:2119–2125.
- 39-Vimeswaran, K.; Berry, D.; Lu, C.; Pilz, S.; Hiraki, L.; Cooper, J.; Dastani, Z.; Li, R.; Houston, D.; Wood, A. Causal relationship between obesity and vitamin D status: Bi-directional mendelian randomization analysis of multiple cohorts. *PLoS Med.* (2013), 10, 1549–1676.
- 40-Wamberg, L.; Christiansen, T.; Paulsen, S.K.; Fisker, S.; Rask, P.; Rejnmark, L.; Richelsen, B.; Pedersen, S.B. Expression of vitamin D-metabolizing enzymes in human adipose tissue—the effect of obesity and diet-induced weight loss. *Int. J. Obes.* (2012), doi:10.1038/ijo.2012.112.
- 41-Zalman, S; Drezner, M. Waltham, MA, (2008). Causes of Vitamin Deficiency and Resistance. In: Up To Date ,Basow, DS (Ed). Up To Date.
- 42-Zella JB, McCary LC, Deluca HF (2003) Oral administration of 1,25-dihydroxyvitamin D<sub>3</sub> completely protects NOD mice from insulin-dependent diabetes mellitus. *Arch Biochem Biophys* 417:77–80.